CASE REPORT article
Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1563553
This article is part of the Research TopicAdvances in skin immunologyView all 8 articles
Spesolimab in Generalized Pustular Psoriasis Complicated by Acrodermatitis Continua of Hallopeau: A Case Report and Mechanistic Insights
Provisionally accepted
- 1Dermatology, Affiliated Hospital of Jining Medical University, Jining, China
- 2Jining Medical University, Jining, Shandong, China
- 3Pathology, Affiliated Hospital of Jining Medical University, Jining, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
1. The patient who suffered from the Generalized pustular psoriasis(GPP) coexisting with Acrodermatitis continua of Hallopeau(ACH) exhibited no significant clinical improvement following conventional therapies, however, the effective manifestation was observed from the patient after the injection of Spesolimab for the first time, signs and symptoms were quickly brought under control.2. Spesolimab, a directly blocking the receptor with a therapeutic antibody, is the first biologic agent via the IL-36 pathway,which associats with the pathogenesis of GPP. So that Spesolimab delivers more precise treament.3. The patient remained free of adverse reactions during the post-treatment observation period until March 10, 2025 4. There are few reports about experience of Spesolimab used in ACH coexisting with GPP, our report provides a case reference for such patiens which has practical significance.
Keywords: spesolimab, generalized pustular psoriasis, Acrodermatitis continua of Hallopeau, IL-36 pathway, IL-1
Received: 20 Jan 2025; Accepted: 21 Apr 2025.
Copyright: © 2025 Hou, Xiao, Wang, Zhang, Ren, Niu, Liu and Lu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Bin Lu, Dermatology, Affiliated Hospital of Jining Medical University, Jining, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.